Non-drug costs associated with outpatient infliximab administration in pediatric inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 7, 2013, Pages 1514-1517

  Wu, May ^a   Sin, Aaron ^b   Nishioka, Fred ^a   Park, K T ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biologics; Costs; Crohn's disease; Infusion units; Pediatric; Remicade; Ulcerative colitis

Indexed keywords

INFLIXIMAB;

ADOLESCENT; ARTICLE; CHILDHOOD DISEASE; CROHN DISEASE; DEMOGRAPHY; DRUG COST; DRUG DATABASE; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON DRUG COST; OUTPATIENT CARE; PRIORITY JOURNAL; REIMBURSEMENT; ULCERATIVE COLITIS;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; MALE; OUTPATIENTS; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879125790     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e318281f4f1     Document Type: Article

References (19)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
2. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
3. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
4. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr. 2000;137:192-196.
5. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother. 2001;35:823-828.
6. Ollendorf DA, Lidsky L. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. Am J Ther. 2006;13:502-506.
7. Johnson R, Freeman EN. Addressing costs and continuity of care through innovative solutions for infused therapies: a collaborative experience with infliximab. Am Health Drug Benefits. 2011;4:39.
8. Condino AA, Fidanza S, Hoffenberg EJ. A home infliximab infusion program. J Pediatr. Gastroenterol Nutr. 2005;40:67-69.
9. Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol. 2000;95:1955-1960.
10. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907-1913.
11. Breynaert C, Ferrante M, Fidder H, et al. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol. 2011;106:778-785.
12. Salary Calculator. http://www.cbsalary.com/salaries/RN/. Accessed March 13, 2013.
13. Bueno H, Ross JS, Wang Y, et al. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA. 2010;303:2141-2147.
14. Kozak LJ, Owings MF, Hall MJ. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13. 2005; (158): 1-199.
15. Lee GE, Lorch SA, Sheffler-Collins S, et al. National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics. 2010;126:204-213.
16. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
17. Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology. 2012;143:365-374.e2.
18. Psaty BM, Redberg RF. Evidence of pharmaceutical innovation and therapeutic enthusiasm: strategies for patent extension. Arch Intern Med. 2012;172:683-684.
19. Carrier MA. Unsettling drug patent settlements: a framework for presumptive illegality. Mich Law Rev. 2009;108:37-80.